Hogan Lovells Advises Martek Biosciences Corporation on Sale to Royal DSM N.V.
21 December 2010
NEW YORK, 21 December 2010 – Hogan Lovells has advised Martek Biosciences Corporation on its sale to Royal DSM N.V. for $1.09 billion in cash in a transaction announced today, which is expected to close in the first or second quarter of 2011.
Martek is a leader in the innovation, development, production and sale of high-value products from microbial sources that promote health and wellness through nutrition.
Representing Martek in the transaction were the following Hogan Lovells lawyers and their practices, led by Corporate Practice partner Michael Silver: Corporate: Michael Silver, Alexander Johnson, Joseph Connolly, William Intner, Roberto Zapata, Mark Schoenfelder, and Julian Seiguer; Antitrust, Janet McDavid; Environmental, Scott Reisch; Intellectual Property, Valerie Brennan; Employee Benefits, William Neff; Tax, Scott McClure; and FDA, Martin Hahn.
About Hogan Lovells
Hogan Lovells combines the breadth of business-oriented legal advice and high-quality service that clients have come to expect through working with its two founding firms – Hogan & Hartson and Lovells.
"Hogan Lovells" or the "firm" refers to the international legal practice comprising Hogan Lovells International LLP, Hogan Lovells US LLP, Hogan Lovells Worldwide Group (a Swiss Verein), and their affiliated businesses, each of which is a separate legal entity. Hogan Lovells International LLP is a limited liability partnership registered in England and Wales with registered number OC323639. Registered office and principal place of business: Atlantic House, Holborn Viaduct, London EC1A 2FG. Hogan Lovells US LLP is a limited liability partnership registered in the District of Columbia.